Amgen Rises as Profit Tops Estimates on Drug Sales

Amgen Inc., the world’s largest biotechnology company, rose the most in eight months after second-quarter profit topped analysts’ estimates on increased demand for its rheumatoid arthritis and bone drugs and the company raised its 2012 forecast.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.